Eurozac Capsule 20mg (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is 20mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20~80mg per day were administered. If no improvement is observed, a dose increase may be considered after several weeks. Doses exceeding 20mg per day should be administered in 2 divided doses (morning and noon), and the maximum dose of 80mg per day should not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks or longer after the start of treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this drug, but psychopharmacologists recognize that the acute signs of depression require drug treatment for several months or longer. It is not known whether the amount of antidepressant needed to relieve symptoms is the same as the amount needed to maintain or sustain stability. 2. Bulimia nervosa Administer 60mg of this drug per day. The daily dose should not exceed 80mg. Measure electrolyte concentrations before starting treatment. 3. Obsessive-compulsive disorder Administer 20~60mg of this drug per day. The daily dose should not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this drug per day. After 6 months of treatment, reassess whether continued treatment is needed. Patients with renal and/or hepatic impairment, patients receiving multiple medications, elderly patients, and patients with concomitant illnesses: Administer a lower dose or reduce the frequency of administration. Adjust the dose as appropriate according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this drug, allow an interval of at least 14 days. Conversely, at least 5 weeks must elapse after discontinuing this drug before starting an MAO inhibitor to treat a psychiatric disorder. Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start treatment with this drug because of the increased risk of serotonin syndrome. For patients who require treatment for a more urgent psychiatric condition, including hospitalization or other interventional procedures, consider administration. It may be necessary to administer linezolid or intravenous methylene blue urgently to a patient already receiving this drug. If no alternative to linezolid or intravenous methylene blue is available and, in a particular patient, the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome, this drug may be discontinued immediately and linezolid or intravenous methylene blue administered. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this drug may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or with intravenous administration of this drug at doses of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults with major depressive disorder or other psychiatric disorders, so careful judgment by a physician is essential when administering to patients in this age group. Patients with hypersensitivity or severe kidney impairment, and those taking MAO inhibitors should not receive this medication. Concurrent use of MAO inhibitors or switching within a certain period poses a high risk of serious side effects. Caution is required for patients with a history of seizures; if seizures occur or increase, treatment should be stopped immediately. Additionally, patients with suicidal tendencies or a history of mania should be closely monitored. As it may affect the heart, patients with heart disease or QT interval prolongation syndrome should ideally undergo an ECG before administration and should stop taking it immediately if any abnormal symptoms arise during treatment. Patients with impaired liver and kidney function should have their dosages adjusted, and diabetic patients may be affected in blood sugar regulation, requiring periodic monitoring of blood glucose levels. This medication can cause pupil dilation, necessitating caution in patients at risk for elevated intraocular pressure or glaucoma. Common side effects such as headaches, nausea, insomnia, fatigue, and diarrhea may occur during treatment, and there is a rare risk of severe allergic reactions, hepatitis, bleeding, and psychiatric symptoms. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, thus the dosage should be reduced gradually under the guidance of a physician. During the early stages of treatment or when changing doses, abnormal behavioral changes such as suicidal thoughts, aggression, and anxiety should be closely monitored, with both patients and caregivers being aware of these symptoms and notifying healthcare professionals immediately. In pregnancy, this medication should only be used when necessary due to potential risks to the fetus, and nursing mothers should consider the need for treatment versus the risks in deciding whether to discontinue nursing. This medication can interact with other drugs, so patients should inform their physician or pharmacist about any concurrent medications, especially when using anticoagulants or other psychiatric medications. Finally, this medication should be kept out of reach of children, and transferring it to another container may adversely affect its quality.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylactic reaction, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disorder, abnormal dreams, depersonalization, elevated mood, happy mood, thought disorder, abnormal libido, bruxism, hypomania, mania, hallucination, agitation, panic attack, suicidal thoughts and behaviors, confusion, attention deficit disorder, dizziness, taste disturbance, hypersomnia, drowsiness, tremors, psychomotor agitation, movement disorder, ataxia, balance disorder, tonic-clonic seizures, convulsions, akathisia, Buccglosal syndrome, serotonin syndrome, memory impairment, blurred vision, pupil dilation, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary events, nosebleed, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, increased tendency to bruising, cold sweats, angioedema, petechial hemorrhage, photosensitivity reaction, purpura, erythema multiforme, arthralgia, myoclonus, myalgia, frequent urination, dysuria, urinary retention, micturition disorder, gynecological bleeding, erectile dysfunction, ejaculation disorder, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, malaise, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, fractures, dizziness, sensory impairment, sleep disorder, asthenia, agitation, anxiety, tremors, headache, anaphylactoid reaction, gradual systemic reaction, severe skin, kidney, liver, or pulmonary-related reactions, hyponatremia, changes in platelet function, aplastic anemia, atrial fibrillation, cataract, cerebrovascular accident, cholestatic jaundice, movement disorders, eosinophilic pneumonia, epithelial necrosis, erythema multiforme, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, exacerbation of movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior

This medication should be stored in a tightly sealed container to protect from air and moisture. It should also be kept away from extreme temperatures, ideally stored at room temperature between 1 degrees Celsius and 30 degrees Celsius.

Appearance

A hard capsule filled with a white to grayish powder: upper part green, lower part light yellow.

Package unit

30 capsules/bottle, 100 capsules/bottle